Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
265.15
-0.42 (-0.16%)
Jul 15, 2026, 10:46 AM EDT - Market open
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$839,568
Profits / Employee
$480,917
Market Cap
16.47B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Insmed | 1,664 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
ASND News
- 8 days ago - Ascendis Pharma price target raised to $280 from $275 at RBC Capital - TheFly
- 13 days ago - 14 value stocks of companies primed for rapid growth through 2028 - Market Watch
- 15 days ago - Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TheFly
- 15 days ago - Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial - GlobeNewsWire
- 18 days ago - Ascendis Pharma added to multiple Russell U.S. Indexes - TheFly
- 18 days ago - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - GlobeNewsWire
- 19 days ago - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma completes Phase 3 PaTHway Trial - TheFly